Anthos Therapeutics ’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

CAMBRIDGE, Mass., November 12, 2023 (BUSINESS WIRE)– Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced today during a Late-Breaking...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials